“T-cell prolymphocytic leukemia (T-PLL), a heterogeneous disease exemplified by two cases and the important role of cytogenetics: a multidisciplinary approach” by Carlos A Tirado et al.
Experimental 
Hematology & Oncology
Tirado et al. Experimental Hematology & Oncology 2012, 1:21
http://www.ehoonline.org/content/1/1/21CASE REPORT Open Access“T-cell prolymphocytic leukemia (T-PLL), a
heterogeneous disease exemplified by two cases
and the important role of cytogenetics: a
multidisciplinary approach”
Carlos A Tirado1*†, Phillip Starshak1†, Paul Delgado2 and Nagesh Rao1Abstract
T-cell prolymphocytic leukemia (T-PLL) is a rare form of leukemia composed of mature T-cells that usually presents
in older people with a median age of 65. Most cases of T-PLL will harbor chromosomal abnormalities involving
14q11.2 (TCR alpha/delta), 14q32 (TCL1) or Xq28 (MTCP-1), abnormalities of chromosome 8, 12p and deletions of
the long arm of chromosomes 5, 6, 11 and 13. Cytogenetics, FISH, comparative genomic hybridization (CGH) , SNP
arrays with high resolution analysis have provided more precisely frequent submicroscopic gene and genomic
lesions as well as breakpoints involved in the pathogenesis of this disease. One of the cornerstones to diagnose
T-PLL are cytogenetic analysis. Here we summarize the current cytogenetic findings and we also describe two
distinct cases of T-PLL where cytogenetics, FISH , morphologic analysis and flow cytometry helped to diagnose
them accurately.
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T-cell prolymphocytic leukemia (T-PLL) is a rare mature
T-cell lymphoproliferative disorder, which suppresses the
immune system through multifactorial processes, thus
predisposing the affected patient to a variety of infec-
tions, and possibly death [1-3]. Common cytogenetic
abnormalities in T-PLL usually include 14q11.2, chromo-
some 8 rearrangements, 11q abnormalities leading to the
deletion of the ATM and MLL genes, and abnormalities
on 12p, 5q, 6q and 13q [3-8]. The presence of a combi-
nation of these fairly unique structural genetic abnor-
malities makes chromosome analysis very crucial and
extremely helpful to get an accurate and definitive diagno-
sis of T-PLL as it supplements the immunophenotypic
and morphological data. Herein, we present two distinct
and diagnostic challenging cases of T-PLL that emphasize
the heterogeneity of this disease but showed cytogenetic* Correspondence: ctirado@mednet.ucla.edu
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reproduction in any medium, provided the oraberrations that helped to confirm the diagnosis of T-PLL.
In addition, we stress the importance of a multidiscipli-
nary approach using the morphologic analysis, flow cyto-
metry, cytogenetic and FISH to accurately diagnose this
disease.Clinical presentation
CASE #1 is an 84 year old male who presented for rou-
tine check-up and was found to have an elevated white
cell count (WBC) of 22.3×10E3/uL. Peripheral blood
(PB) smear showed lymphocytosis that appeared small
to intermediate in size with mildly abundant cytoplasm,
round to ovoid nuclear contours, and inconspicuous nu-
cleoli. Some showed cytoplasmic blebs (Figure 1A). Flow
cytometry of the PB revealed that these atypical lympho-
cytes were of mature phenotype lacking TdT expression
and were positive for alpha-beta T-cell receptor. In
addition, the neoplastic T-cells showed bright expression
of CD8 and moderate uniform expression of CD52 but
no significant loss of pan T-cell antigens was noted
(Figures 2A, 2C).Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 A: Peripheral blood smear with lymphocytes, note cytoplasmic blebs. B: Bone marrow aspirate with numerous lymphocytes, note
prominent nucleoli.
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infiltrate of atypical lymphocytes that were highlighted by
a TCL1 immunostain and a diagnosis of 10% involvement
of the marrow by atypical CD8 positive mature T-cell lym-
phocytes was made.
CASE #2 is a 52 year old female with complaints of
cough and congestion. A physical exam was notable for
tachypnia. Her WBC was 189×10E3/uL. PB smear revea-
led numerous immature appearing lymphocytes that wereFigure 2 A: Scatter-plot showing predominant population of T-cells w
expression. C: Scatter-plot showing predominant population of T-cells witintermediate to large in size, had moderate amount of
cytoplasm, round nuclear contours, open chromatin, and
prominent centrally placed nucleoli consistent with
prolymphocytes.
The BM aspirate showed numerous immature appea-
ring lymphocytes with centrally placed nucleolus remi-
niscent of prolymphocytes (Figure 1B). In addition, flow
cytometry showed that the neoplastic cells were mature
T-cells as they lacked expression of CD34, HLA-DR, andith bright CD8 expression (arrow) B (density-plot): uniform CD52
h dim CD4 expression (arrow) D: And heterogeneous CD52 expression.
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These neoplastic T-cells also were positive for CD4 and
showed moderate expression of CD52 (Figures 2B, 2D).
A BM biopsy revealed a conspicuous infiltrate of large
atypical lymphocytes with prominent nucleolus in a back-
ground of mutlilineage hematopoiesis and a TCL1 immu-
nostain showed that these atypical lymphocytes were
strongly positive.
Cytogenetics studies
Cytogenetic studies of the bone marrow was per-
formed using conventional cytogenetic techniques. The
karyotypes were described according to the ISCN 2009
nomenclature [9].
CASE #1
An abnormal clone was seen in 12/20 with loss of the
Y chromosome, a (X;14) translocation, a three-way trans-
location between chromosomes 1q, 12p and 4q, unbalan-
ced rearrangement of 3p, deletions of 13q and 22q. The




An abnormal clonal population with numerical and struc-
tural abnormalities including an isochromosome 8q,
structural abnormalities of 2p, 4p, 14q and 18q, deletion
11q, monosomy 17, and up to four marker chromosomes
of unknown origin. The ISCN karyogram was: 48,XX,add
(2)(p13),add(4)(p14),i(8)(q10),del(11)(q23),add(14)(q11.2),
-17,del(18)(q11.2),+2 ~ 4mar (cp10) (Figure 3B).
Fish studies
FISH analysis was performed using the following pro-
bes from Abbott Molecular (Des Plaines, Illinois 60018):Figure 3 A: Karyotype 45,t(X;14)(q28;q11.2),-Y,t(1;12;4)(q42;p13;q31
B: Karyotype 48,XX,add(2)(p13),add(4)(p14),i(8)(q10), del(11)(q23),add(14)(q11The Vysis LSI IGH/MYC/CEP 8 Tri-Color Dual Fusion
Probes, the Vysis LSI MYC Dual Color Break Apart
Rearrangement Probe, the Vysis TRA/D Break Apart
Rearrangement probe, the Vysis CLL FISH Probe Kit and
the Vysis LSI BCR/ABL Dual color, Dual Fusion Trans-
location probe.
CASE #1
An abnormal pattern suggestive of a TCRA/D gene re-
arrangement was seen in 96/300 (32.0%) of the cells
examined by FISH and 3 copies of 8q24 (MYC) in 19/
300 (6.3%) indicating trisomy 8q. The ISCN nomencla-
ture was described as: nuc ish(MYCx3)(19/300), (ATM,
TP53x2)(300),(TRA/Dx2)(50TRA/D sep 30TRA/Dx1)(96/
300) (Figure 4A, 4B).
CASE #2
An abnormal signal pattern with 3–7 signals for 8q24 in
84.0% (254/300) and 3 copies of chromosome 22q in 8.3%
(25/300) of the nuclei examined. In addition, these studies
also detected evidence of TCRA/D gene rearrangement in
90.0% (270/300) of the nuclei examined and a deletion of
the 30 TCRA/D in 26.6% (80/300) of the cells examined
by FISH. The ISCN nomenclature was described as: nuc
ish (MYCx3~7,IGH@)x2(252/300), (ABL1x2, BCRx3)(25/
300),(MLLx2)(300), (ATMx2)(300),(TCRA/Dx2)(50TCRA/
D sep 30TCRA/Dx1)(190/300)/(50TCRA/Dx2, 30TCRA/
Dx1)(50TCRA/D con 30TCRA/Dx1)(80/300), (TP53x2)
(300) (Figure 4C, 4D, 4E).
Discussion
The two cases seen in the present study demonstrate the
immunophenotypic heterogeneity in T-PLL as in case #1
the neoplastic T-cells were CD8 positive while in case#2
the neoplastic T-cells were CD4 positive. In fact, T-PLL
can also be double positive for CD4/CD8 or double.3), add(3)(p13),del(13)(q14q34),del(22)(q12q13)(12)/46,XY(8).
.2),-17,del(18)(q11.2),+2 ~ 4mar(cp10).
Figure 4 A: FISH dual-color break apart probe for the C-MYC gene showing three intact copies B: FISH dual-color break apart probe
for T-cell receptor alpha-delta showing a split signal suggesting a rearrangement of TCRA/D. C: FISH showing multiple copies the C-MYC
gene (red color). D: FISH dual-color break apart probe for T-cell receptor alpha-delta showing a split signal suggesting a rearrangement of TCRA/D in
90% of the cells E: 27% of these abnormal cells also showed a deletion of the 30 TRCA/D.
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sion of CD52 is consistently expressed in T-PLL, and
therefore this leukemia is a prime target for campath
(aletuzumab) therapy, this feature is not unique to T-PLL
as other T-cell lymphoma/leukemias as well as non-
neoplastic T-cells are often positive for CD52.
From a morphologic stand-point, the two cases were
also quite different with case #1 showing a more mature
small lymphocytic appearance with inconspicuous nu-
cleoli whereas case#2 showed larger lymphocytes with
prominently placed central nucleolus (prolymphocytes).
In fact, it is recognized that a subset of T-PLL cases will
have a small lymphocytic appearance and these cases
are often referred to as the small cell variant of T-PLL
[2,5]. Finally, the clinical scenarios were quite diffe-
rent in both cases with case#1 having a more indolentpresentation whereas case#2 had a more typical ag-
gressive presentation.
Complex karyotypes with structural abnormalities
[1-8,10-13] including 14q11.2 rearrangements as seen in
our cases is observed in 80% of T-PLL cases. These ab-
normalities include inv(14)(q11.2q32) or the t(14;14)(q11;
q32) [3]. Rarely, the t(X;14)(q28;q11) or t(Y;14)(q12;q11)
[1]. The 14q32.1 region is very important because it is the
locus of the TCL1 gene and any rearrangement at this
locus is sufficient to activate TCL1 gene expression
through juxtaposition of TCRA sequences [4,12]. TCR
stimulation leads to rapid recruitment of TCL1, AKT and
tyrosine kinases to membrane associated activation com-
plexes [4]. However, TCL1 can also be activated by hypo-
methylation or loss of methylation on one allele of the
TCL1 promoter region [7,12]. Supporting this is the
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expressed in approximately 70% of T-PLL cases [2]. A
study, using SNP-array and gene expression array tech-
nologies, 734 genes were found to be directly linked to inv
(14), which were differentially expressed and involved in
leukemia, cell cycle regulation, apoptosis and DNA repair
[3].
Chromosome 8 anomalies as seen in our case are also
common in T-PLL. Maljaei et al. [6] and Olivera et al.
[1] suggest in their study the synergistic effect as a result
of the increased expression of the MYC gene (8q24) due
to an i(8q) and a deleterious loss of TSG on 8p such
as MTUS1 when 8p is deleted in the pathogenesis of
T-PLL.
Other findings in T-PLL that may be overlooked by
conventional cytogenetics are anomalies of 11q [13] like
in case 1 and abnormalities of chromosome 22 like in
case 2. Both abnormalities were also confirmed by CGH
[10] and SNP-array studies [3]. The minimal deleted
regions on chromosome 22 include the genes SMARCB1
(which encodes the SWI/SNF related proteins which
might be involved in chromatin remodeling, chromosomal
stability, and checkpoint control) and CHECK, which
seem to be inactivated by biallelic mutation during T-PLL
progression. This supports the hypothesis that there might
be additional tumor suppressor genes (TSG) on chro-
mosome 22 spanning from the centromere to the 22q12.1
region [11].
CGH studies [10] suggests that there are multiple addi-
tional chromosomal abnormalities involved in T-PLL that
were previously under recognized by conventional karyo-
type and FISH analysis including gain of genetic material
in many different chromosomal regions including 5p
(62%), and 14q (37%), 6p and 21 (both 25%) and loss of
genetic material on 13q (37%), 6q, 7q, 16q, 17p, and 17q
(25%).
Durig et al. [3] using SNP-based array technique also
found deletions in 6p, 8p, 11p, 11q, 12p, 13q and gains
in 4q, 5p, 6p and 8q and 14q. Nowak et al. [4] found
homozygous deletions on chromosomes 14 and 7 in the
T-cell receptor loci, 12p, 5p; heterozygous deletions in-
volving 13q, 17p and 17q and abnormalities involving 5q,
6p, 12p, 13q and 17p.
In conclusion, with the textbook cytogenetic abnorma-
lities revealed in both of these cases that are highly as-
sociated with T-PLL we were able to come to a correct
diagnosis. Of special note case#2 was initially incorrectly
diagnosed as T-lymphoblastic leukemia highlighting that
these cases can be diagnostic challenging. Morphologic
evaluation, clinical data and techniques with higher reso-
lution such as CGH and SNP-based genomic mapping
will elucidate common deletions and gains of chromo-
somal material unique to T-PLL. Further studies using
gene expression profiling techniques are needed to betterunderstand and open more avenues for treatment targets
of this disease.
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